Development
Thermo Fisher Scientific Inc.
TMO
$415.15
$0.610.15%
NYSE
| 12/31/2023 | 09/30/2023 | 07/01/2023 | 04/01/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -4.93% | -0.96% | -2.58% | -9.38% | 6.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -4.93% | -0.96% | -2.58% | -9.38% | 6.99% |
| Cost of Revenue | -5.17% | -1.91% | 0.91% | 2.91% | 25.44% |
| Gross Profit | -4.56% | 0.44% | -7.41% | -23.66% | -12.20% |
| SG&A Expenses | -6.52% | -7.69% | -4.57% | -7.00% | 4.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.94% | -3.63% | -0.72% | 0.09% | 18.50% |
| Operating Income | -0.25% | 12.85% | -11.00% | -39.43% | -26.18% |
| Income Before Tax | -0.46% | 14.32% | -24.22% | -46.93% | -6.18% |
| Income Tax Expenses | -23.12% | 70.97% | -73.74% | -84.72% | -14.78% |
| Earnings from Continuing Operations | 2.03% | 13.15% | -18.35% | -41.80% | -5.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 1,100.00% | 766.67% | 75.00% | 40.00% | 300.00% |
| Net Income | 3.43% | 14.72% | -18.21% | -41.81% | -4.95% |
| EBIT | -0.25% | 12.85% | -11.00% | -39.43% | -26.18% |
| EBITDA | -0.49% | 9.24% | -7.06% | -30.25% | -16.19% |
| EPS Basic | 4.50% | 16.50% | -16.94% | -40.90% | -4.22% |
| Normalized Basic EPS | 2.51% | 21.14% | -10.99% | -42.29% | -25.08% |
| EPS Diluted | 5.38% | 16.62% | -16.82% | -40.82% | -4.18% |
| Normalized Diluted EPS | 2.77% | 21.44% | -11.00% | -42.14% | -24.70% |
| Average Basic Shares Outstanding | -1.02% | -1.53% | -1.53% | -1.53% | -0.76% |
| Average Diluted Shares Outstanding | -1.27% | -1.77% | -1.52% | -1.77% | -1.26% |
| Dividend Per Share | 16.67% | 16.67% | 16.67% | 16.67% | 15.38% |
| Payout Ratio | 0.12% | 0.00% | 0.41% | 0.95% | 0.20% |